Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-30

pARylation-mediated regulation of cancer pathways

Objective

Poly(ADP)ribosylation (pARylation) is an important post-translational modification of proteins that affects diverse biological processes such as DNA damage repair, apoptosis and transcription. The conjugation of Poly(ADP)-ribose (pADPr) to target proteins is mediated by members of the Poly(ADP)-ribose polymerase (ARTD/PARP) protein family. ADPr can be attached either as a single moiety or as chains forming poly-ADPr polymers (pADPr). The best-studied member of the ARTD/PARP family is ARTD1/PARP1, a DNA nick sensor enzyme that is activated following DNA damage. ARTD1/PARP1 is able to pARylate itself and a number of other protein targets, such as histones and DNA repair proteins, modulating their activity. Another member of this super-family is the telomeric ARTD/PARP, Tankyrase 1 (ARTD5/TNKS1), which plays an important role in maintaining telomere integrity, by pARylating its telomere partner, TRF1. Since the discovery that defects in homologous recombination sensitise cancer cells to PARP inhibitors there has been a renewed interest in ARTD/PARPs as attractive therapeutic targets. Furthermore, similarly to kinases and phosphorylation it seems likely that ARTD/PARPs and pARylation will have significant roles in the controls of a diverse range of cellular mechanisms. Using a combined approach of RNA interference (RNAi), drug treatment and mass spectrometry-based proteomic analysis, I propose to identify and characterise novel mono- and poly-(ADP)ribosylation targets, specific to particular ARTD/PARPs. This will help to resolve how (ADP)r conjugation regulates biological processes and contributes to the survival and maintenance of cancer cells. Moreover, using pathway specific reporter cell lines I will address the specific contribution of mAR/pARylated proteins for the regulation of several cancer-related signalling pathways. Ultimately, these studies will reveal novel and promising pARylation-based therapeutic targets for cancer treatment.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-PEOPLE-2010-RG
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MC-ERG - European Re-integration Grants (ERG)

Coordinator

INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG
EU contribution
€ 30 000,00
Address
OLD BROMPTON ROAD 123
SW7 3RP London
United Kingdom

See on map

Region
London Inner London — West Kensington & Chelsea and Hammersmith & Fulham
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0